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ABSTRACT 
 
Posttranscriptional processing of RNA molecules is a common strategy to enlarge the 
structural and functional repertoire of RNomes observed in all three domains of life. 
Fragmentation of RNA molecules of basically all functional classes has been reported to yield 
smaller non-protein coding RNAs (ncRNAs) that typically possess different roles compared to 
their parental transcripts. Here we show that a valine tRNA-derived fragment (Val-tRF) that is 
produced under certain stress conditions in the halophilic archaeon Haloferax volcanii is 
capable of binding to the small ribosomal subunit. As a consequence of Val-tRF binding 
messenger RNA is displaced from the initiation complex which results in global translation 
attenuation in vivo and in vitro. The fact that the archaeal Val-tRF also inhibits eukaryal as 
well as bacterial protein biosynthesis implies a functionally conserved mode of action. While 
tRFs and tRNA halves have been amply identified in recent RNA-seq project, Val-tRF 
described herein represents one of the first functionally characterized tRNA processing 
products to date.  
 
  
 3 
INTRODUCTION 
 
Over the last few decades various non-protein-coding RNA (ncRNA) classes have been 
identified as pivotal players in regulating gene expression (reviewed in refs. 1,2). Recent deep 
sequencing studies have uncovered thousands of ncRNA candidates in all three domains of 
life thus indicating a so far buried layer of transcriptome complexity.1,3 Thereby it is 
intriguing that ncRNA transcripts with well assigned or proposed functions, such as small 
nucleolar RNAs or vault RNAs, can serve as precursors for downstream cleavage events 
generating yet another functional class of RNA pieces such as micro RNAs (miRNAs).4,5 
Subsequent transcriptome-wide studies showed that post-transcriptional cleavage events of 
RNAs with assigned cellular functions into smaller fragments fulfilling other, mostly 
regulatory, roles is rather the rule than the exception (reviewed in ref. 6). Posttranscriptional 
fragmentation to generate smaller functional RNAs involves all sorts of transcripts including 
protein coding (e.g. ref. 7) as well as ncRNAs (e.g. refs. 8-10) and is thus potentiating the 
regulatory and functional repertoire of cellular RNomes significantly.6 One of the most amply 
reported substrates for such RNA fragmentation events in recent years involves tRNAs 
(reviewed in refs. 11-15).  
tRNA molecules have been shown to be cut in the anticodon loop thus giving rise to tRNA 
halves. Fragmentation can also occur elsewhere in the molecule therefore generating shorter 
pieces typically referred to as tRNA-derived fragments (tRFs) with a size between ~18-26 
nucleotides. tRNA-derived fragments (tRFs) were first observed already several decades ago 
in human tumor tissue16 and E. coli cells,17 and have subsequently been reported in model 
organisms from all three domains of life. Nevertheless, tRFs and tRNA halve molecules were 
initially regarded as either by-products of tRNA biogenesis or random degradation 
intermediates. Only recently more dedicated research uncovered that tRNA pieces can fulfill 
regulatory roles in cell metabolism and thus some represent functional ncRNA molecules. 
Typically tRNA fragmentation is not a global intracellular phenomenon but affects only 
particular tRNA isoacceptors and has often been shown to be stress dependent or cell-type 
specific (reviewed in refs. 11,12). While some of the endonucleases involved in tRNA halves 
production in eukaryal species have been identified, such as angiogenin, Rny1 or Dicer, tRF 
biogenesis in prokaryal organisms is largely unknown. It has been discussed that post-
transcriptional tRNA modifications can guide or expel processing RNases during tRNA 
fragmentation.12,18 Also the functional repertoire of tRFs and tRNA halves is huge and seems 
to vary between cell types and incubation conditions. For example, recently two studies in 
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human breast cancer cells reported that tRNA-derived fragments harbor tumor- and 
metastasis-suppressive activity19 while Honda et al. revealed tRNA halves to have 
proliferation effects on estrogen receptor-positive breast cancer cells.20 In mouse sperm tRNA 
halves have been identified to represent a paternal epigenetic factor that may contribute to 
intergenerational inheritance.21 Even though our understanding of the tRF and tRNA halves 
biology is still in its infancy, the emerging picture form a plethora of recent studies is that 
tRNA pieces represent biologically relevant entities rather than mere degradation products of 
full-length tRNAs. 
Even though recent transcriptome-wide RNA-seq studies led to the discovery of tRNA pieces 
in many different model organisms, functional or mechanistic insight into their physiological 
roles remained sparse with only few exceptions (e.g. refs. 10,19-23). Here we report on the 
functional characterization of a tRF deriving from Val-tRNA (Val-tRF) of the halophilic 
archaeon Haloferax volcanii. In a recent publication we could show that this 26 residue long 
5’ tRF is produced under alkaline stress and is capable of binding to the ribosome in vitro and 
in vivo.24 Here we provide functional evidence that this ribosome-associated small ncRNA 
(rancRNA; ref. 25) attenuates global protein biosynthesis by competing with mRNA binding 
to the small ribosomal subunit and thus affecting translation initiation.  
 
 
RESULTS 
 
The inhibitory potential of Val-tRF is functionally conserved in all three domains of life 
In a recent genomic screen designed at identifying small ribosome-associated ncRNAs 
(rancRNAs) in H. volcanii, we detected several tRFs, especially originating from the 5’ part 
of a subset of tRNAs (5’ tRFs), to co-purify with ribosomal particles in a stress-dependent 
manner.24 A 26 nucleotide long 5’ fragment deriving from valine tRNA showed high 
abundance during alkaline stress and inhibited H. volcanii-based  in vitro translation and in 
vitro peptide bond formation assays upon binding to the small  ribosomal subunit.24 To study 
the role of this Val-tRF in a more physiological setting we established a metabolic labeling 
approach to study protein biosynthesis in vivo. To this end we introduced the synthetic Val-
tRF into H. volcanii cells using a polyethylene glycol-mediated transformation procedure26 
and subsequently assessed the amounts of newly synthesized proteins by means of in vivo 35S-
methionine incorporation. Indeed after introduction of chemically synthesized Val-tRF 
markedly reduced levels of newly synthesized proteins were observed (Fig. 1). Inhibition 
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efficiency was in a similar range compared to well-known ribosome-targeted antibiotics such 
as puromycin or thiostrepton. Importantly, introduction of an Ile-tRF, an analogous tRF 
deriving from a comparable region of isoleucine tRNA, served as specificity control. 
Significantly, Ile-tRF, a fragment that was not present in our rancRNA screen,24 did not 
inhibit metabolic labeling. Similarly, a DNA-variant of the Val-tRF (Val-tDF) had no effect 
on the in vivo protein production in H. volcanii cells (Fig. 1B, C and Supplementary Fig. 
S1). Since both tRNAs and ribosomes are universally conserved components of the 
translational machinery, we tested if the Val-tRF-mediated translation repression is 
functionally conserved in other species as well. In order to elucidate this we tested the H. 
volcanii Val-tRF in eukaryotic and bacterial systems, namely in S. cerevisiae and E. coli, 
respectively. To study the in vivo effect of the Val-tRF in yeast we performed an analogous 
metabolic labeling approach using S. cerevisiae spheroplasts.27 Introduction of the Val-tRF 
into the yeast spheroplasts by electroporation resulted in a significant reduction of protein 
biosynthesis (Fig. 1D). The Val-tRF-mediated reduction in the yeast metabolic labeling assay 
was comparable to the effects of a previously characterized yeast rancRNA (rancRNA_18) 
which is an mRNA exon-derived ncRNA shown to target and regulate yeast ribosomes.7 The 
translation inhibitor cycloheximide served as protein synthesis inhibition control (Fig. 1D). 
Importantly, also in this setting Ile-tRF was not able to inhibit protein biosynthesis in yeast 
cells in a comparable manner. To corroborate these findings, in vitro translation reactions 
were performed using yeast cell extracts or a commercially available E. coli in vitro 
translation system as well as a peptidyl transferase assay based on purified E. coli ribosomes. 
Addition of the H. volcanii Val-tRF, but not the Ile-tRF, reproducibly inhibited in vitro 
protein biosynthesis in both the eukaryal and bacterial systems (Supplementary Fig. S2A, B, 
C). Additionally, during the peptidyl transferase assay the Val-tRF was able to decrease the 
extent of peptide bond formation by about 40% (Supplementary Fig. S2D). Cumulatively, 
these data suggest that the archaeal Val-tRF is capable of also inhibiting bacterial and 
eukaryotic translation systems. This implies that the mode of action, and thus likely also the 
ribosomal target site, is conserved in all three domains of life. 
 
Val-tRF competes with efficient translation initiation 
Protein biosynthesis proceeds in four phases, namely translation initiation, elongation, 
termination and recycling. In principle all of these four phases, which are characterized by 
complex interactions between the ribosome, tRNAs, mRNA, and additional protein factors 
could be affected by Val-tRF. It has been shown over the years that translation regulation 
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mainly occurs on the level of initiation, since this is the most critical and rate-limiting step of 
protein biosynthesis.28,29 Preferential binding of the Val-tRF to the small ribosomal subunit in 
vitro and in vivo24 led to the hypothesis that this tRF might interfere with the formation of the 
translation initiation complex. In order to test this we performed toeprinting experiments 
using purified H. volcanii 70S (or 30S) particles, deacylated E. coli initiator tRNAfMet and an 
mRNA analog carrying a unique AUG codon.30 The formation of the initiation-like 
complexes 30S/tRNAfMet/mRNA or 70S/tRNAfMet/mRNA was assessed by the reverse 
transcription inhibition-based toeprinting assay in the absence or presence of Val-tRF (Fig. 
2A). The primer extension stops at positions +15/+16 (whereas the A in the start codon is 
assigned to position +1) provides a measure for the formation of the initiation-like complex, 
since it is dependent on both 70S ribosomes (or 30S subunits, respectively) and initiator 
tRNA (Fig. 2B and Supplementary Fig. S3A). Addition of Val-tRF interfered with this 
complex formation in a dose dependent manner. Importantly, under the highest tested 
concentration, the Ile-tRF in contrast had no effect on complex formation (Fig. 2C and 
Supplementary Fig. S3B). Thus this assay indicates that the Val-tRF specifically interferes 
with the formation of translation initiation-like complexes.  
 
Val-tRF interferes with mRNA binding to the small ribosomal subunit 
The most likely explanation for blocking the formation of the initiation complex in the above 
setting is that the Val-tRF either interferes with P-site tRNA or mRNA binding to the 
ribosome. Intuitively, the first alternative seems to be more plausible since tRFs arise from 
mature and thus fully functional tRNA molecules.11 Even though secondary structure 
predictions of Val-tRF did not suggest any stable structure resembling a tRNA anticodon-
stem loop,24 we experimentally tested binding competition between ribosome bound tRNAs 
and Val-tRF. Therefore 5’-[32P]-labeled Val-tRF was incubated with purified H. volcanii 70S 
ribosomes in the presence of increasing amounts of yeast tRNA and binding efficiencies were 
analyzed via nitrocellulose filter binding. Even at a massive molar excess of tRNA over 
ribosomes no significant reduction in Val-tRF binding was observed (Fig. 3A). Under the 
applied binding conditions (no mRNA and high tRNA excess) one P-site located tRNA 
molecule per ribosome is expected.31 Indeed under these conditions we observed tRNA 
binding saturation to H. volcanii ribosome at one molecule per 70S at the highest tRNA 
concentration used (Fig. 3A). However, when the ribosome binding experiments were 
repeated in the presence of increasing amounts of in vitro transcribed mRNA markedly 
reduced and dose-dependent Val-tRF binding became apparent (Fig. 3B). The half maximum 
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inhibitory mRNA concentration (IC50) was determined to be 800 nM. Importantly, this effect 
was apparently not dependent on the mRNA sequence since a very similar binding 
competition was evident when the homopolymeric mRNA-analog poly(U) was used 
(Supplementary Fig. S4A).  These data therefore indicate that Val-tRF does not inhibit 
ribosome-mRNA association by interfering with the Shine-Dalgarno/anti-Shine-Dalgarno 
interaction, a principle often exploited by other prokaryal small ncRNAs regulators (reviewed 
in ref. 32). This interpretation is in line with the fact that H. volcanii does actually not use the 
Shine-Dalgarno mechanism for translation initiation.33 
Val-tRF cross-links to nucleotides in close proximity to the 30S mRNA channel 
Since the inhibitory effect of the Val-tRF on translation was observed not only in H. volcanii 
but also in eukaryal and bacterial systems, we assumed that a functionally conserved region of 
the small ribosomal subunit is targeted. Saturation binding experiments with radiolabeled Val-
tRF and purified 30S or 70S H. volcanii particles revealed a single binding site in the small 
ribosomal subunit (Supplementary Fig. S4B). Employing Cy5 end-labeled Val-tRF in 
solution binding experiments using microscale thermophoresis allowed us to determine a Kd 
of 773 ± 17 nM. The binding mode of Val-tRF to the 30S subunit does not entirely depend on 
simple sequence complementarity to 16S rRNA since the all-DNA variant Val-tDF did not 
bind significantly to 30S subunits and was also inactive in attenuating protein synthesis and 
peptide bond formation (Fig. 1 and Supplementary Fig. S2D and S5A).  
To gain a more comprehensive insight into the Val-tRF binding site on the ribosome and thus 
about the functional mechanism of tRF-mediated translation regulation, crosslinking 
experiments utilizing 4-thio uracil containing Val-tRF was performed. A synthetic version of 
the 5’-[32P]-end labeled Val-tRF RNA carrying three photo-reactive 4-thio uracil bases 
(named Val-tRF(4SU)) was bound to H. volcanii 70S ribosomes and cross-linked at 366 nm. 
Subsequently free Val-tRF(4SU) was removed via gel filtration and rRNAs as well as the 
ribosomal proteins from the cross-linked 70S complex were extracted and analyzed by 
scintillation counting. It turned out that 99% of the radiolabel was found in the rRNA rather 
than in the r-protein fraction thus suggesting the Val-tRF 30S binding site to be composed of 
rRNA. Running the cross-linked rRNAs on a denaturing gel revealed a preferentially cross-
linking and therefore 32P-labeling of the 16S rRNA (Supplementary Fig. S5B). This is 
consistent with our previously published data showing that Val-tRF predominantly binds to 
and acts on the small ribosomal subunit.24 To narrow down the 16S rRNA cross-linking site, 
complementary DNA oligo-driven RNase H cleavage assays were performed using anti-sense 
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strands distributed all over the 16S rRNA. By tracing the 32P label on the two 16S rRNA 
cleavage products on denaturing gels (data not shown) allowed us to narrow down the cross-
linking position(s) between nucleotides 829 and 1473 in the 16S rRNA 3' region (E. coli 
rRNA nomenclature is used here and throughout). To identify the Val-tRF(4SU) cross-linking 
sites on the nucleotide level, primer extension analyses on the 3’ region of 16S rRNA were 
performed. Specific primer extension stops occurring only after irradiation at 366 nm in the 
presence of Val-tRF(4SU) were reproducibly identified at three 16S rRNA regions, namely at 
nucleotides A968/A969 and A978/U979 close to helix 31, as well as at C1403/C1404 in the 
heart of the decoding center (Fig. 4A, B and 5A). Consistent with the data shown in Figures 
1, 2 and 3B, an mRNA analog was able to compete with cross-linking of Val-tRF(4SU) to 
these 16S rRNA sites, while Ile-tRF had no effect (Fig. 4C and Supplementary Fig. S6). To 
substantiate the functional relevance of the cross-linking sites, additional competition 
experiments were performed.  Since all three cross-linking regions are located close to 
functional centers of the small ribosomal subunit that are also targeted by antibiotics, we 
repeated the Val-tRF crosslinking in the presence of kanamycin, neomycin, spectinomycin or 
tetracyclin. It turned out that the latter two antibiotics, which have been shown to bind in 
close proximity to the crosslinking sites surrounding helix 31 (ref. 34), efficiently inhibited 
Val-tRF(4SU) crosslinking (Fig. 4D). The aminoglycosides kanamycin and neomycin that 
bind to helix 44 in the decoding center had, however, no effect on cross-linking efficiencies. 
Highlighting the three crosslinking regions in the context of the available bacterial 30S crystal 
structure showed that they all surround the mRNA channel of the small ribosomal subunit 
(Fig. 5B). Especially the two cross-linked regions C1403/C1404 in helix 44 and A968/A969 
in the loop of helix 31 are of special interest since they are located in immediate proximity to 
the mRNA path. Thus these data further corroborate the observation that Val-tRF is 
competing with mRNAs for ribosome binding. 
 
DISCUSSION 
 
Here we report on the biochemical characterization of a 5’ tRNA fragment (tRF) 
deriving from the Val-tRNA(GAC) isoacceptor of H. volcanii regarding its function and 
cellular target. We provide evidence that this stress-dependent Val-tRF binds to the small 
ribosomal subunit in immediate vicinity of the mRNA channel and dims protein biosynthesis 
on a global level (Fig. 1-5). Since tRNAs are key molecules of protein biosynthesis, inhibition 
of translation as a consequence of full-length tRNA destruction seems to be a plausible 
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scenario. However, this picture appears to be too simplistic, since it has been shown in several 
studies that the steady-state levels of genuine tRNAs do not change significantly upon tRNA 
fragmentation.20,35-37 It follows that the mechanism by which tRNA pieces negatively affect 
protein biosynthesis is more intricate.22,24,38 In fact several lines of experimental evidence 
indicate that H. volcanii Val-tRF competes with mRNA binding rather than with tRNA 
binding (Fig. 3) and thus affects translation initiation. However we note that also peptide 
bond formation is inhibited (Supplementary Fig. S2D and ref. 24), therefore a role of Val-
tRF during the elongation phase of protein production cannot be excluded. The mechanism by 
which Val-tRF exerts its biological role seems to be highly conserved since the archaeal tRF 
is capable of attenuating protein biosynthesis in vivo and in vitro in a eukaryal (S. cerevisiae) 
and bacterial (E. coli) system as well (Fig. 1D and Supplementary Fig. S2). While we do not 
have evidence that a similar tRNA fragment actually is produced in yeast or E. coli, the mere 
fact that the Val-tRF from the halophilic archaeon H. volcanii can function in species from 
other domains argues for a fundamental principle of translation regulation. In many prokaryal 
species translation regulation mediated by small ncRNAs (sRNAs) involves the ribosome 
binding site on the mRNAs including the Shine-Dalgarno sequence.39 Thus it appears 
reasonable to assume that Val-tRF interferes with the Shine-Dalgarno/anti-Shine-Dalgarno 
interaction during translation initiation. However is has been demonstrated that the archaeon 
H. volcanii does not utilize the Shine-Dalgarno system to start protein biosynthesis.33 This 
probably explains why Val-tRF was such a competent in vivo inhibitor of protein synthesis in 
the eukaryal model S. cerevisiae (Fig. 1D). The main advantage of RNA regulators compared 
to protein-mediated processes is their immediate availability upon rapidly changing 
environmental conditions. tRFs are in that respect ideally suited to function as stress 
regulators since the mother molecule, the genuine tRNA, is already available and only a 
single phosphodiester cut, by a yet unknown processing regime, is sufficient to generate the 
regulatory ncRNA species. While the exact processing mechanism is so far unclear, we could 
show that a protein enzyme with RNAse activity is likely responsible for Val-tRF biogenesis 
(Supplementary Fig. S7). H. volcanii Va-tRF is produced primarily upon alkaline stress and 
quickly attenuates global protein biosynthesis by targeting the small ribosomal subunit.24 This 
allows the cells to reduce their metabolic activities under these harsh conditions, which is also 
reflected by a severely retarded growth phenotype.  
The investigated Val-tRF is a bona fide ribosome-associated-ncRNA (rancRNA) since 
it targets and affects the functional competence of the small ribosomal subunit. Our data 
demonstrate that Val-tRF  is capable of binding to the 30S subunit in the absence of additional 
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protein cofactors with a Kd in the nM range, an affinity comparable to ribosome targeting 
antibiotics such as tetracylin (Kd ~1 µM; ref. 40) or neomycin (Kd ~0.8 µM; ref. 41). Various 
rancRNAs have been identified in different organisms in several research groups and 
represent a so far poorly studied class of regulatory ncRNAs (reviewed in ref. 25). Val-tRF 
(this study) and the mRNA-derived rancRNA_18 in yeast7 are among the best characterized 
rancRNAs so far and the picture that emerges is that rancRNAs are involved in the first wave 
of stress response. While Val-tRF in H. volcanii is produced and thus functional upon alkaline 
stress, rancRNA_18 is required under hyperosmotic growth conditions in S. cerevisiae. From 
an energetic point of view targeting the translation machinery directly for regulatory purposes 
is reasonable since it allows a swift and global effect on cell metabolism which is crucial for 
survival under challenging environmental conditions. The Val-tRF characterized in this study 
therefore fulfills all criteria to be considered as new entry in the ever-growing list of 
regulatory ncRNA.   
 
MATERIALS AND METHODS 
 
Strains and growth conditions 
Haloferax volcanii strain H26 was grown aerobically at 42°C in complex medium (2.9 M 
NaCl, 150 mM MgSO4 x 7H2O, 60 mM KCl, 4 mM CaCl2, 50 mM Tris/HCl (pH 7.2), 0.45 % 
(w/v) tryptone, 0.275 % (w/v) yeast extract). S. cerevisiae strain BY4742 was grown in Sc-
Leu medium (yeast synthetic complete drop out medium –Leu; Sigma Aldrich) at 30°C. 
 
Metabolic labeling in H. volcanii and S. cerevisiae 
For metabolic labeling in H. volcanii the protocol for spheroplast preparation and nucleic acid 
transformation has been adapted from refs. 26,42. H. volcanii cells were grown in 10 ml rich 
medium into the exponential phase to an OD600 of 0.6, pelleted during 10 min centrifugation 
at 4,400 x g at room temperature and resuspended in 2 ml buffered spheroplasting solution 
containing 1 M NaCl, 27 mM KCl, 50 mM Tris/HCl (pH 8.5) and 15% (w/v) sucrose. Cells 
were pelleted again and resuspended in 600 µl buffered spheroplasting solution. Cells were 
then divided into three equal aliquots in 2 ml Eppendorf tubes, 20 µl of 0.5 M EDTA (pH 8.0) 
was added and the tubes were inverted three times and incubated for 10 min at room 
temperature. 180 µl H. volcanii spheroplasts were then added to 30 µl of a premixed solution 
containing 15 µl unbuffered spheroplasting solution (1 M NaCl, 27 mM KCl, 15% (w/v) 
sucrose), 5 µl 0.5 M EDTA (pH 8.0), 1 µl 35S-methionine (1,000 Ci/mmol, 10 mCi/ml), RNA 
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(200 pmol) or antibiotic (f.c. 0.6 mM thiostrepton or puromycin) and incubated for 5 min at 
room temperature. Transformation was then initiated by adding 250 µl 60% (v/v) 
polyethylene glycol 600 in unbuffered spheroplasting solution and samples were mixed by 
carefully inverting the tube and incubated at room temperature for 30 min. The samples were 
then diluted with 1 ml of spheroplast dilution solution (15 % sucrose (w/v), 3.2 M NaCl, 109 
mM MgSO4 x 7H2O, 112 mM MgCl2 x 6H2O, 71 mM KCl, 4 mM CaCl2, 15 mM Tris/HCl 
(pH 7.2)), and pelleted for 10 min at 3,300 x g at room temperature. Subsequently 500 µl 
regeneration solution containing 0.45 % (w/v) tryptone, 0.275 % (w/v) yeast extract, 0.1 % 
(w/v) casamino acids, 15 % (w/v) sucrose, 2.5 M NaCl, 85 mM MgSO4 x 7H2O, 88 mM 
MgCl2 x 6H2O, 56 mM KCl, 4 mM CaCl2, and 12 mM Tris/HCl (pH 7.2) was carefully added 
to the pellet (without resuspending the pellet). Spheroplasts were then incubated for 20 min at 
42°C and subsequently resuspended. The extent of labeled proteins was monitored after 
pelleting the spheroplasts followed by lysing with the addition of 50 µl H2O and incubation at 
95°C for 2 min. The lysate was passed over an illustra Microspin G25-Sepadex column (GE 
Healthcare) and the proteins were then separated by 11% Tricine-SDS-PAGE. The newly 
synthesized proteins were monitored by phosphorimaging (FLA-3000) and quantified with 
the densiometric program Aida Image Analyzer. The following synthetic oligonucleotides 
were introduced with this approach into H. volcanii spheroplasts: Val(GAC)-tRF: 5’-
GGGUUGGUGGUCUAGUCUGGUUAUGA-3’, Ile-tRF: 5’- 
GGGCCAAUAGCUCAGUCAGGUUGAGC-3’, Val-tDF: 5’-
GGGTTGGTGGTCTAGTCTGGTTATGA-3’ 
Metabolic labeling in S. cerevisiae was performed as described.7 Briefly, yeast spheroplasts 
were mixed with 100 pmol of synthetic RNA (rancRNA_18: 5’-
AGGAAAAGGUGAAAAGAA-3’ or tRFs) and introduced into the cell via electroporation. 
After electroporation 1 ml YPD/1 M sorbitol and 1 μl 35S-methionine (1,000 Ci/mmol, 10 
mCi/ml) were added and the reactions were incubated for 1 hour at 30°C. The extent of 
labeled proteins was monitored by TCA precipitation and subsequent liquid scintillation 
counting or by running the labeled proteins on an SDS polyacrylamide gel followed by 
quantification by phosphorimaging.7 
 
Peptidyl transferase assay 
The assay was performed in 25 μl of appropriate reaction buffer containing 10 pmol 70S 
ribosomes, 0.8 pmol N-acetyl-[3H]Phe-tRNA (15,000 cpm/pmol), puromycin (f.c. 1 mM) and, 
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as indicated, 100 pmol of the synthetic tRF or tDF (see above). For H. volcanii ribosomes a 
high salt buffer composed of 2 M KCl, 30 mM Tris/HCl (pH 7.6), 0.4 M NH4Cl, 60 mM 
Mg(OAc)2, 7 mM β-mercaptoethanol, 2 mM spermidine, 0.05 mM spermine was used. The 
transpeptidation reaction was initiated by the addition of 12.5 μl cold methanol (f.c. 33%) and 
incubated for 3.5 h on ice. For E. coli ribosomes binding buffer (f.c. 20 mM Hepes/KOH pH 
7.6, 6 mM Mg(OAc)2, 150 mM NH4Cl, 4 mM β-mercaptoethanol, 2 mM spermidine, 0.05 
mM spermine) was used. The reaction was started by the addition of puromycin and incubated 
for 30 min at 37°C. Reaction products were extracted into ethyl acetate and quantified by 
liquid scintillation counting as described previously.24 
 
In vitro translation 
Yeast S30 extract preparation and subsequent in vitro translation was performed as described 
in detail previously.7 In vitro translation reactions in E. coli (New England BioLabs) were 
performed according to the manufacturer`s instructions. 
 
In vitro binding studies 
Binding studies of Val-tRF to ribosomal particles were performed using a dot blot-filtering 
device24 or microscale thermophoresis. For the filter binding assay 5 pmol of H. volcanii 70S 
or 30S subunits were incubated with varying amounts of 5’-[32P]-end-labeled synthetic tRF in 
25 μl 1x TMN buffer (f.c. 20 mM Tris acetate (pH 7.6), 100 mM NaOAc and 5 mM 
Mg(OAc)2)  or 1x Hfx binding buffer (f.c. 20 mM Hepes/KOH pH 7.6, 150 mM Mg(OAc)2, 
150 mM NH4Cl, 4 mM β-mercaptoethanol, 2 mM spermidine, 0.05 mM spermine), 
respectively. After 30 min of incubation at 42°C the reactions were filtered through a 
nitrocellulose membrane (0.45 μM diameter) using a vacuum device, followed by two 
washing steps with ice cold buffer. For binding competition assays 5 pmol of H. volcanii 70S 
ribosomes were incubated in a total volume of 25 μl with 4 pmol 5'-[32P]-labeled synthetic 
Val-tRF and indicated amounts (5 to 400 pmol) of unlabeled competitor RNA (tRFs, yeast 
bulk tRNA, poly(U), or in vitro transcribed mRNA coding for r-protein L12 (43) in 1x TMN 
or 1x Hfx binding buffer (for tRNA competition). Reactions were assembled at room 
temperature and incubated at 42°C for 15 min before filtration through the nitrocellulose 
membrane. After two washing steps with the respective ice-cold buffer, membranes were 
exposed to phosphor-imaging screens. The signals were monitored and quantified as 
described above. Microscale thermophoresis measurements were performed on a Monolith 
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NT.115 apparatus (NanoTemper Technologies, Munich, Germany). Therefore constant 
concentrations of a 5’-Cy5-end-labeled synthetic Val-tRF (10 nM) were assembled in a series 
of sixteen 1:1 dilution steps of H. volcanii 70S ribosomal particles dissolved in 1 x TMN 
(starting with 25 μM) in a final reaction volume of 20 μl. Reactions were soaked in standard 
capillaries and the thermophoretic movement was monitored with a laser (on for 30 s and off 
for 5 s; at a laser voltage of 20%). The Kd was calculated from three independent 
measurements with the according NanoTemper Software. 
 
 
Toeprinting analysis 
Toeprinting analysis was performed as described elsewhere44 with some minor changes. For 
primer extension, 6.2 pmol of [32P]-labeled primer 5`- CGTTAATCTGTGATG-3` were 
annealed to 25 pmol in vitro transcribed and purified mRNA carrying a short open reading 
frame coding for MFKRSIYV in a reaction volume of 10 μl (20 mM Hepes/KOH pH 7.6, 150 
mM NH4Cl, 4 mM β-mercaptoethanol, 2 mM spermidine, 0.05 mM spermine). 15 pmol H. 
volcanii 70S ribosomes (or H. volcanii 30S subunits) were incubated for 15 min at 40°C in a 
total volume of 7 µl in toeprinting buffer (29 mM Hepes/KOH pH 7.5, 29 mM NH4Cl, 29 mM 
Mg(OAc)2, 1.7 mM β-mercaptoethanol, 0.29 M KCl) in the presence of various amounts of 
synthetic Val-tRF RNA (20, 50, or 100 pmol) or Ile-tRF RNA (100 pmol). Then 2 µl of the 
above mentioned mRNA/primer mix was added as well as 1 µl of E. coli tRNAfMet (200 pmol) 
and the sample was incubated at 40°C for 15 min. Subsequently for primer extension 2.5 µl 
RT Mix (20 mM Tris/HCl pH 7.4, 20 mM NH4Cl, 100 mM MgCl2, 14.5 mM dNTPs, 1 U/µl 
AMV reverse transcriptase) was added and the sample was incubated for 15 min at 40°C. The 
reaction was terminated by the addition of 5 volumes 9:1 EtOH/0.3 M NaOAc (pH 5.5). 
Precipitated and pelleted cDNA was dissolved in formamide dye and separated on 7.5% 
polyacrylamide gels containing 7 M urea. Gels were vacuum-dried at 70°C for 2 h and 
exposed to phosphor-imaging screens. The signals were monitored and quantified as already 
described above. 
 
Cross-linking studies 
For the cross-linking experiments, a synthetic Val-tRF RNA carrying three photo-reactive 4-
thiouridine residues at positions +5, +13, and +22 was used (Val-tRF(S4U)). Depending on 
the downstream analysis, the Val-tRF(S4U) was either radioactively 5’ end labeled or used as 
unlabeled RNA. 5 pmol of H. volcanii ribosomal particles (70S, 50S, 30S) were incubated 
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with 10 - 50 pmol of Val-tRF(S4U) or competitor (tRFs, poly(U) or antibiotics) in a final 
volume of 25 μl 1x TMN for 15 min at 37°C or 42°C. Cross-linking was either performed 
during this incubation step or afterwards during an additional incubation for 15 min on ice. 
For cross-linking, reaction tubes were opened and a hand-held UV lamp was placed in a 
distance of 3.5 cm. Cross-linking was performed at 366 nm for 15 min. For subsequent primer 
extension analyses, 125 μl TE/SDS buffer (10 mM Tris/HCl pH 7.4, 100 mM NaCl, 5 mM 
EDTA, 0.5% (w/v) SDS) was added and phenol/chloroform extraction was performed. To 
determine whether rRNA or ribosomal proteins were crosslinked under these conditions, 32P 
5’ end labeled Val-tRF(4SU) was crosslinked to H. volcanii 70S. Subsequently non-reactive 
Val-tRF(4SU) was removed via gel filtration using Illustra MicroSpin S-300 HR columns 
(GE Healthcare) according to the manufacturer’s instructions. Subsequently a 
phenol/chloroform extraction was performed and the amount of crosslinked 32P-Val-tRF(4SU) 
in the aqueous as well as the organic phases was quantified by liquid scintillation counting. 
 
RNase H cleavage assays 
Prior to RNase H cleavage, 25 pmol 5' [32P]-end-labeled Val-tRF(4SU) was cross-linked to 
2.5 pmol 30S subunits and 16S rRNA was phenol/chloroform extracted. RNase H cleavage 
experiments were performed in a final volume of 10 μl 1x TMN buffer. 0.5 μg extracted 
cross-linked 16S rRNA was denatured at 95°C for 2 min. 10 pmol of DNA oligonucleotide 
complementary to specific sites on the 16S rRNA (16S_454-473: 5’-
TATTACCGCGGCGGCTGGCA-3’, 16S_624-644: 5’-ATTACGGGATTTCACTCCTAC-
3’, 16S_740-759: 5’-ATCGTTTACAGCTAGGACTA-3’, 16S_829-848: 5’-
ATCCTTGCGGACGTACTTCC-3’, 16S_942-964: 5’-
TCATCAACCTGATCGTCATCACT-3’, 16S_977-995: 5’-TGCACCTCCTCTCTACAGC-
3’, 16S_1109-1130: 5’-CCTTCCTCCGCTTTAGCAGCGG-3’, 16S_1215-1237: 5’-
TTTAGGAGATTAGCGTTCTCTTT-3’, 16S_1330-1351: 5’-
GGCGGTGTGTGCAAGGAGCAGG-3’, 16S_1451-1473: 5’-
AGGAGGTGATCCAGCCGCAGATT-3’) were added and incubated at 70 °C for 2 min and 
for 30 min at 37°C. 1 U of RNase H was added and cleavage was performed at 37 °C for 30 
min. RNase H cleavage was stopped by snap freezing of reactions. Cleavage products were 
analyzed on 5% polyacrylamide gels containing 7 M urea. After staining with ethidium 
bromide, gels were vacuum-dried at 70°C for 2 h and exposed to phosphor-imaging screens. 
The signals were monitored with a phosphor imager (FLA-3000; Fuji Photo Film). 
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Primer extension analysis 
In order to detect the sites of Val-tRF(4SU) cross-link on the 16S rRNA by reverse 
transcription,45 the DNA primer (16S_454-473: 5’-TATTACCGCGGCGGCTGGCA-3’, 
16S_624-644: 5’-ATTACGGGATTTCACTCCTAC-3’, 16S_740-759: 5’-
ATCGTTTACAGCTAGGACTA-3’, 16S_829-848: 5’-ATCCTTGCGGACGTACTTCC-3’, 
16S_942-964: 5’-TCATCAACCTGATCGTCATCACT-3’, 16S_977-995: 5’-
TGCACCTCCTCTCTACAGC-3’, 16S_1109-1130: 5’-CCTTCCTCCGCTTTAGCAGCGG-
3’, 16S_1215-1237: 5’-TTTAGGAGATTAGCGTTCTCTTT-3’, 16S_1330-1351: 5’-
GGCGGTGTGTGCAAGGAGCAGG-3’, 16S_1451-1473: 5’-
AGGAGGTGATCCAGCCGCAGATT-3’) was radioactively labeled in a first step. For ten 
reactions 50 pmol of primer were incubated with 2 μl γ-[32P]-ATP and 10 U T4 PNK in a 
final volume of 20 μl 1x PK buffer (70 mM Tris/HCl pH 7.5, 5 mM EDTA, 10 mM MgCl2) at 
37°C for 20 min. Subsequently the reaction was stopped by heating at 95°C for 2 min. For 
annealing, 2 μl 16S rRNA (100-200 ng/μl) were mixed with 2 μl primer (corresponds to 5 
pmol) and 4 μl 2.5x HY buffer (62.5 mM Tris/HCl pH 8.4, 75 mM KCl). After an initial 
denaturation at 95°C for 2 min, the annealing was performed at 42°C for 30 min. Samples 
were briefly spun down and 10 μl extension mixture, containing 1 μl dNTPs (1.25 mM each) 
and 0.4 U AMV reverse transcriptase in 1x EX buffer (0.1 M Tris/HCl pH 8.4, 10 mM 
MgCl2, 10 mM DTT), were added. For sequencing reactions, ddNTPs (f.c. 0.2 mM) were 
additionally added to the reaction. After incubation at 42°C for 45 min, the reactions were 
stopped by adding 2 volumes stop solution (4 M NH4Ac, 20 mM EDTA). Subsequently, 
nucleic acids were ethanol (120 μl) precipitated at -20°C for at least 20 min in the presence of 
1 μl GlycoBlue (Ambion). Subsequently, samples were pelleted at 18,000 x g for 20 min, 
washed with 70% EtOH and resuspended in 12 μl loading buffer (60% (v/v) formamide, 0.1% 
(w/v) bromphenol blue, 0.1% (w/v) xylene cyanol). The cDNA products were run in 1x TBE 
at 40 W on denaturing 6 or 8% polyacrylamide gels containing 7 M urea, respectively. Gels 
were vacuum-dried at 70°C for 1 h and exposed to phosphor-imaging screens. The signals 
were monitored with a phosphor imager. 
 
SUPPLEMENTARY DATA 
Supplementary Data are available online. 
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FIGURE LEGENDS 
 
Figure 1. Val-tRF inhibits translation in vivo. (A) Under specific stress conditions, 
particularly under alkaline stress and elevated magnesium conditions (24), the valine 
tRNA(GAC) isoacceptor is processed to give rise to a 26-residue long 5’-tRF. (B) Metabolic 
labeling in H. volcanii spheroplasts in the absence (-) or presence of Val-tRF, Ile-tRF or an all 
DNA version of Val-tRF, named Val-tDF. The antibiotics thiostrepton (Thio) and puromycin 
(Pmn) served as translation inhibition controls. The background (bkg) represents radioactive 
bands measured in the absence of any incubation. A representative SDS page of the newly 
synthesized 35S-labled proteins is shown (upper gel). The coomassie stained gel part 
underneath the autoradiogram serves as loading control. (C) Quantification of the lane 
intensities obtained in the metabolic labeling experiments in H. volcanii are shown whereas 
the activity in the absence of any transformed synthetic RNA (-; mock) is set to 100%. The 
background values (see above) were subtracted from all other samples. The mean and 
standard deviations of four independent experiments are shown. (D) The H. volcanii Val-tRF 
also inhibits metabolic labeling in S. cerevisiae spheroplasts. The mean and standard 
deviations of four independent experiments are shown. Cycloheximide (CHX) and an already 
characterized yeast rancRNA (rancRNA_18) served as inhibition controls. A representative 
SDS PAGE of newly synthesized proteins after the 35S-methionine spike is shown. The 
coomassie stained gel part underneath the autoradiogram serves as loading control. In (C) and 
(D) significant differences relative to the mock control (-) were determined using the two-
tailed paired Student’s t-test (***p < 0.001, **p < 0.01, *p < 0.05).  
 
 
Figure 2. Val-tRF interferes with the efficient establishment of a translation initiation-like 
complex as monitored by toeprinting. (A) Schematic representation of the toeprinting assay 
using H. volcanii 30S subunits (gray) or 70S ribosomes (not shown), initiator tRNAfMet and an 
mRNA. Reverse transcription (dotted arrow) of the [32P]-radiolabeled primer (solid arrow) is 
terminated in case of a stable 30S/tRNAfMet/mRNA complex formation. (B) The obtained 
cDNA products were separated on denaturing polyacrylamide gels and visualized by 
phosphorimaging. The toeprinting signal depends on the presence of tRNAfMet and H. volcanii 
70S. U, A, C, G denote dideoxy sequencing lanes. The relevant mRNA sequence is shown left 
to the gel and the start codon (AUG) and the toeprinting sites are highlighted. (C) The 
toeprinting signals obtained in the presence of H. volcanii 70S ribosomes and tRNAfMet can be 
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inhibited by increasing amounts of Val-tRF. The Ile-tRF at the highest tested concentration 
did not interfere with toeprinting and served as specificity control. A representative 
autoradiograph of a toeprinting gel is shown in the lower panel. Quantification of four 
independent toeprinting experiments is shown above the gel whereas the toeprinting signals in 
the absence of any added tRF was taken as 100%.  
 
 
Figure 3. tRNA and mRNA binding competition with Val-tRF. (A) Radiolabeled Val-tRF 
was bound to H. volcanii 70S ribosomes in the absence or presence of increasing amounts of 
unlabeled yeast tRNA. The mean and the standard deviations of three independent binding 
competition experiments are shown underneath the dot blot. Signals measured in the absence 
of ribosomal particles (-70S) were subtracted from all experimental points. The added molar 
excess of tRNA over ribosomes is indicated below. (B) Val-tRF binding was monitored as a 
function of increased mRNA concentration. The mean and the standard deviations of two 
independent binding competition experiments are shown. The added molar excess of mRNA 
coding for r-protein L12 over ribosomes is shown. The half maximum inhibitory 
concentration (IC50) is given. 
 
Figure 4. Val-tRF photo-crosslinking to the 30S ribosomal subunit. (A) The sites of 
crosslinking at 366 nm of Val-tRF carrying 4-thio uracil, Val-tRF(4SU), to the 970 and 980 
regions of the 3’-domain of 16S rRNA of H. volcanii 30S subunits was monitored by primer 
extension analysis. Experiments in the presence of Val-tRF(4SU) without irradiation or in the 
presence of unmodified Val-tRF with irradiation served as controls.  U, A, C, G denote 
dideoxy sequencing reactions. The relevant rRNA sequence is shown left to the gel and the 
crosslinked nucleotides are indicated by asterisks. Note that the reverse transcriptase always 
stops one nucleotide 3’ of the actually crosslinking site. (B) Sites of Val-tRF(4SU) 
crosslinking to positions 1403/1404 of 16S rRNA helix 44 in the decoding center were 
identified by primer extension analysis. U, A, C denote dideoxy sequencing reactions. The 
relevant rRNA sequence is shown left to the gel and the crosslinked nucleotides are indicated 
by asterisks. (C) The Val-tRF(4SU)-dependent crosslinks can be competed by the addition of 
unmodified Val-tRF or mRNA, but not by Ile-tRF. Note that all lanes shown originate from 
the same gel. Below the autoradiogram image the quantification of the crosslinked bands 
compared to control bands is given. The intensities of the primer extension stops in the 
reaction containing Val-tRF(4SU) in the absence of any competitor was taken as 1.0. ‘n.d.’ 
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denotes an experiment not performed in this particular crosslinking experiment shown (refer 
to Supplementary Figure S6 for more data). (D) Val-tRF(4SU) crosslinking in the presence of 
the antibiotics kanamycin (Kan), neomycin (Neo), spectinomycin (Spt), or tetracycline (Tet).  
 
Figure 5. Val-tRF crosslinks to sites in close proximity to the 30S mRNA channel. (A) Sites 
of Val-tRF(4SU) crosslinking in proximity to helix 31 and helix 44 are indicated by red dots 
in the schematic representation of the E. coli 16S rRNA secondary structure model. (B) 
Interface view (left) and A-site view (right) of the small ribosomal subunit from T. 
thermophilus (pdb file 2J00; (46)). The Val-tRF crosslinking sites are depicted in red and a 
30S-bound mRNA piece is shown in green. The 16S rRNA is in blue and the ribosomal 
proteins are depicted in gray.  
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